Article Details

Pfizer says Ibrance gives more survival time to some breast-cancer patients

Retrieved on: 2021-03-25 11:26:15

Tags for this article:

Click the tags to see associated articles and topics

Pfizer says Ibrance gives more survival time to some breast-cancer patients. View article details on hiswai:

Excerpt

Ibrance, which received regulatory approval in the U.S. as a first-line treatment in 2017, generated $5.4 billion in revenue in 2020. Pfizer's stock is up ...

Article found on: www.marketwatch.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up